Circulating tumour cells in non-metastatic breast cancer: a prospective study.

[1]  Sabine Kasimir-Bauer,et al.  Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies , 2009, Breast Cancer Research and Treatment.

[2]  E. Yagüe,et al.  The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy , 2011, British Journal of Cancer.

[3]  Anne Vincent-Salomon,et al.  Clinical Significance of Immunocytochemical Detection of Tumor Cells Using Digital Microscopy in Peripheral Blood and Bone Marrow of Breast Cancer Patients , 2004, Clinical Cancer Research.

[4]  M. Delgado-Rodríguez,et al.  Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosis , 2003, International journal of cancer.

[5]  G. T. Budd,et al.  Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival , 2006, Clinical Cancer Research.

[6]  S. Krishnamurthy,et al.  Detection of minimal residual disease in blood and bone marrow in early stage breast cancer , 2010, Cancer.

[7]  M. Loda,et al.  Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer , 2010, British Journal of Cancer.

[8]  Rosalba Miceli,et al.  Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy , 2005, Breast Cancer Research and Treatment.

[9]  Tanja Fehm,et al.  Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.

[10]  S. Narod,et al.  Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers , 2009, Breast Cancer Research and Treatment.

[11]  D. Tait,et al.  Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Sotiriou,et al.  Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[14]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Jacob,et al.  Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer. , 2011, Biomarkers in medicine.

[16]  G. Kallergi,et al.  Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. , 2010, Cancer letters.

[17]  R. Gill.  Understanding Cox's regression model. , 1982, Experientia. Supplementum.

[18]  Thomas Rau,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[19]  A. Mbbs.  Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer , 2010 .

[20]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[21]  E. van Marck,et al.  Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer , 2006, British Journal of Cancer.

[22]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Nesland,et al.  Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer , 2006, International journal of cancer.

[24]  E. Yagüe,et al.  Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients , 2012, British Journal of Cancer.

[25]  Jong-Hyeon Jeong,et al.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002, The New England journal of medicine.

[26]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T M Therneau,et al.  Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. , 1995, Biometrics.

[28]  Ugo Pastorino,et al.  MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.

[29]  M. Beckmann,et al.  Abstract S6-5: Prognostic Relevance of Circulating Tumor Cells in the Peripheral Blood of Primary Breast Cancer Patients , 2010 .

[30]  S. Singletary,et al.  Prognostic Factors in Node-Negative Breast Cancer: A Review of Studies With Sample Size More Than 200 and Follow-Up More Than 5 Years , 2002, Annals of surgery.

[31]  A. Vincent-Salomon,et al.  Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  L. Kiesel,et al.  HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.

[33]  S. Loibl,et al.  Prospective monitoring of circulating tumor cells in breast cancer patients treated with primary systemic therapy—A translational project of the German Breast Group study GeparQuattro , 2007 .

[34]  Black Mm,et al.  Nuclear structure in cancer tissues. , 1957 .

[35]  J. Stebbing,et al.  Circulating tumour cells as more than prognostic markers. , 2009, The Lancet. Oncology.

[36]  Karen Page,et al.  Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. , 2012, Genome research.

[37]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[38]  T. Fehm,et al.  Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial , 2010, Clinical Cancer Research.

[39]  T. Eberlein,et al.  Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011 , 2009 .

[40]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[41]  R C Coombes,et al.  Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment , 2008, British Journal of Cancer.

[42]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[43]  L. Frati,et al.  Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  York Springer,et al.  Ajcc Cancer Staging Manual. 7th Ed. New , 2010 .